Regeneron Pharmaceuticals, Inc. REGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 4.82B | 4.33B | 4.42B | 4.50B | 4.58B |
| Total Depreciation and Amortization | 512.90M | 528.60M | 540.00M | 543.70M | 525.10M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 513.10M | -194.20M | -390.20M | -602.30M | -472.40M |
| Change in Net Operating Assets | -997.40M | 18.20M | 439.50M | 532.60M | 440.30M |
| Cash from Operations | 4.85B | 4.68B | 5.01B | 4.98B | 5.07B |
| Capital Expenditure | -1.02B | -920.90M | -899.70M | -898.40M | -849.30M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -300.00K | -3.30M | -3.30M | -3.30M | -14.50M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 430.60M | 220.00M | -802.50M | 272.60M | 365.00M |
| Cash from Investing | -589.40M | -704.20M | -1.71B | -629.10M | -498.80M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.02B | 756.10M | 738.40M | 635.90M | 223.30M |
| Repurchase of Common Stock | -3.73B | -3.90B | -3.79B | -3.97B | -4.01B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -383.00M | -378.50M | -374.30M | -370.30M | -277.60M |
| Other Financing Activities | 0.00 | 0.00 | 0.00 | -10.30M | -10.30M |
| Cash from Financing | -3.10B | -3.52B | -3.43B | -3.72B | -4.07B |
| Foreign Exchange rate Adjustments | -1.00M | -1.90M | -1.20M | 300.00K | -100.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.16B | 450.40M | -122.40M | 634.70M | 501.30M |